Suppr超能文献

紫杉醇涂层球囊治疗非恶性输尿管狭窄的长期疗效

Long-term outcomes of paclitaxel-coated balloons for non-malignant ureteral strictures.

作者信息

Kallidonis Panagiotis, Spiliopoulos Stavros, Papadimatos Panagiotis, Katsanos Constantinos, Liourdi Despoina, Tsaturyan Arman, Karnabatidis Dimitrios, Liatsikos Evangelos, Kitrou Panagiotis

机构信息

Department of Urology, University of Patras, Patras, Greece.

2nd Department of Radiology, National and Kapodistrian University of Athens, Athens, Greece.

出版信息

World J Urol. 2022 May;40(5):1231-1238. doi: 10.1007/s00345-022-03952-1. Epub 2022 Mar 5.

Abstract

PURPOSE

To evaluate the clinical efficacy and safety of drug-coated balloon (DCB) ureteroplasty for the management of non-malignant ureteral strictures.

MATERIAL AND METHODS

A prospective "off-label" monocentric single-arm pilot study investigating the safety and efficacy of drug-coated balloon (DCB) (Lutonix; BD, USA) was performed. Twenty-five patients with benign ureteral strictures related to uretero-enteric anastomosis (n = 13); lithiasis (n = 5), post-surgical complications (iatrogenic n = 5), transplanted kidney (n = 1) and post-radiotherapy (n = 1) were included. Following lesion crossing, predilatation was performed using 4-7 mm high-pressure balloon catheter (5-6Fr) with a balloon pressure of 6-7 atm based on the manufacturer's recommendation. In the absence of rupture of the ureteral wall, the DCB was dilated for 4 min. across the lesion. The process was repeated if deemed necessary to a maximum of three stricture dilatations. We analysed both clinical and radiological primary patency (no signs of ipsilateral hydronephrosis or improvement of the existing residual dilatation at the follow-up examinations) and secondarily safety endpoints.

RESULTS

Mean lesion length was 40 ± 28.5 mm. Mean time follow up was 36 months ± 10.46 months. Strictures were located at upper ureteric (12%), lower ureteric (32%), ureterovesical anastomosis (4%) and uretero-enteric anastomosis (52%) levels. The overall radiological success at 1-year follow-up was 88% (22/25 patients). In 56% patients (14/25 patients with primary patency) the nephrostomy catheter was removed 21 days following a single DCB procedure. In 32% (8/25 patients) an additional dilatation sessions were required for maintaining the ureteral patency. The overall failure rate at 1-year follow-up was 12% (3/25 patients). Only one case of febrile urinary tract infection in a female patient (acute pyelonephritis) was encountered after the first dilatation.

CONCLUSIONS

Paclitaxel-coated balloon ureteroplasty proved to be safe and effective for the treatment of non-malignant ureteral strictures. Larger studies are warranted to validate these promising initial results.

摘要

目的

评估药物涂层球囊(DCB)输尿管成形术治疗非恶性输尿管狭窄的临床疗效和安全性。

材料与方法

进行了一项前瞻性“非标签”单中心单臂试点研究,以调查药物涂层球囊(DCB)(Lutonix;美国BD公司)的安全性和有效性。纳入了25例良性输尿管狭窄患者,病因包括输尿管肠吻合术相关(n = 13);结石(n = 5)、手术后并发症(医源性,n = 5)、移植肾(n = 1)和放疗后(n = 1)。病变通过后,根据制造商的建议,使用4 - 7毫米高压球囊导管(5 - 6Fr)进行预扩张,球囊压力为6 - 7个大气压。在输尿管壁未破裂的情况下,将DCB在病变部位扩张4分钟。如有必要,可重复该过程,最多进行三次狭窄扩张。我们分析了临床和放射学主要通畅情况(随访检查时无同侧肾积水迹象或现有残余扩张改善)以及次要安全终点。

结果

平均病变长度为40 ± 28.5毫米。平均随访时间为36个月 ± 10.46个月。狭窄位于输尿管上段(12%)、下段(32%)、输尿管膀胱吻合处(4%)和输尿管肠吻合处(52%)水平。1年随访时的总体放射学成功率为88%(22/25例患者)。在56%的患者(14/25例主要通畅患者)中,单次DCB手术后21天拔除了肾造瘘导管。在32%(8/25例患者)中,需要额外进行扩张以维持输尿管通畅。1年随访时的总体失败率为12%(3/25例患者)。首次扩张后仅1例女性患者发生发热性尿路感染(急性肾盂肾炎)。

结论

紫杉醇涂层球囊输尿管成形术被证明治疗非恶性输尿管狭窄安全有效。需要更大规模的研究来验证这些有前景的初步结果。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验